<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01980680</url>
  </required_header>
  <id_info>
    <org_study_id>Agonist5</org_study_id>
    <nct_id>NCT01980680</nct_id>
  </id_info>
  <brief_title>The Exogenous Progesterone Free Luteal Phase After GnRHa Trigger - a Pilot Study in Normo-responder IVF Patients</brief_title>
  <acronym>GnRHa trigger</acronym>
  <official_title>The Exogenous Progesterone Free Luteal Phase After GnRHa Trigger - a Randomized Controlled Pilot Study in Normo-responder IVF Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peter Humaidan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regionshospitalet Viborg, Skive</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      After hCG trigger a large amount of exogenous progesterone is used for luteal phase support
      in many countries until 10th week of gestation. Instead we suggest the use of two small doses
      of hCG after the trigger during the early luteal phase after GnRHa trigger, promoting the
      endogenous progesterone production from the corpora lutea (CL).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ongoing pregnancy rate per patient</measure>
    <time_frame>10th week of gestation.</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Agonist trigger</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Agonist trigger Buserelin 0,5 mg and Pregnyl (hCG)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hCG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>hCG trigger Pregnyl (hCG) and Progesterone and Estradiol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hCG</intervention_name>
    <arm_group_label>Agonist trigger</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progesterone and Estradiol</intervention_name>
    <arm_group_label>hCG</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 20 and 40

          -  Normal menstrual cycles: 25-34 days

          -  Oligomenorrhea/amenorrhea or polycystic syndrome (defined according to the Rotterdam
             criteria 2004)

          -  BMI &gt;18 and &lt;35 kg/m2

        Exclusion Criteria:

          -  Patients with &gt;14 follicles on day of trigger

          -  Previous hyperresponse with OHSS development

          -  Previous low response (less than 3 oocytes on a high dose of FSH stimulation)

          -  Endocrine disorders
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Fertility Clinic, Regional Hospital of Skive</name>
      <address>
        <city>Skive</city>
        <zip>7800</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter S Humaidan, MD</last_name>
      <phone>+45 89 27 40 13</phone>
      <email>peter.humaidan@sygehusviborg.dk</email>
    </contact>
    <contact_backup>
      <last_name>Alice T Mikkelsen, Nurse</last_name>
      <phone>+45 89 27 40 85</phone>
    </contact_backup>
    <investigator>
      <last_name>Peter S Humaidan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 28, 2013</study_first_submitted>
  <study_first_submitted_qc>November 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2013</study_first_posted>
  <last_update_submitted>April 9, 2018</last_update_submitted>
  <last_update_submitted_qc>April 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Regionshospitalet Viborg, Skive</investigator_affiliation>
    <investigator_full_name>Peter Humaidan</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Progesterone</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

